Patents by Inventor Sandra J. Hofstead

Sandra J. Hofstead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5708146
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## (I) in whichD is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ C1.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: January 13, 1998
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5622929
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## in which D is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ C1.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: January 23, 1992
    Date of Patent: April 22, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5606017
    Abstract: Provided are drug/ligand compounds of Formula (I): ##STR1## in which D is a drug moiety;n is an integer from 1 to 10;p is an integer from 1 to 6;Y is O or NH.sub.2.sup.+ Cl.sup.- ;z is 0 or 1;q is about 1 to about 10;X is a ligand; and,A is a Michael Addition Adduct.In a preferred embodiment, the ligand is an immunoglobulin, preferably a chimeric antibody or fragment thereof. Also provided are formulations comprising as an active ingredient a compound of Formula (I), intermediates useful for preparing the compounds of Formula (I), processes for preparing the compounds of Formula (I), and methods for using the compounds of the invention.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: February 25, 1997
    Assignee: Bristol-Myers Squibb Company
    Inventors: David Willner, Pamela A. Trail, H. Dalton King, Sandra J. Hofstead, Robert S. Greenfield, Gary R. Braslawsky
  • Patent number: 5087567
    Abstract: An antitumor antibiotic designated BMY-42428 is produced by fermentation of Actinomadura madurae ATCC-53806. The BMY-42428 antibiotic exhibits both antimicrobial and antitumor activities.
    Type: Grant
    Filed: January 12, 1990
    Date of Patent: February 11, 1992
    Assignee: Bristol-Myers Squibb Company
    Inventors: Thomas T. Dabrah, Grace A. Hesler, Sandra J. Hofstead, Kin S. Lam, Jacqueline M. Mattei, Daniel R. Schroeder, Koji Tomita
  • Patent number: 5001112
    Abstract: Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.
    Type: Grant
    Filed: March 17, 1989
    Date of Patent: March 19, 1991
    Assignee: Bristol-Myers Company
    Inventors: Sandra J. Hofstead, James A. Matson, Kin S. Lam, Salvatore Forenza, James A. Bush, Koji Tomita